A Single-Arm Phase II Clinical Trial of Cabozantinib (XL184) in Patients With Previously Treated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases With and Without C Met Amplification
Phase of Trial: Phase II
Latest Information Update: 10 Aug 2018
At a glance
- Drugs Cabozantinib (Primary)
- Indications Brain metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- 30 Jul 2018 Planned End Date changed from 1 Jun 2028 to 1 Jul 2024.
- 30 Jul 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Jul 2019.
- 13 Jan 2016 Planned End Date changed from 1 Dec 2027 to 1 Jun 2028 as reported by ClinicalTrials.gov record.